Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Creative Bloq on MSN18h
Hitachi means business with bold new visual identity
At the centre of the new brand identity is an evolved logo design that maintains the same boldness of Hitachi's heritage ...